Get the Stockscreener App
23.39
1.35%
-0.32
After Hours:
23.39
Ultragenyx Pharmaceutical Inc stock is traded at $23.39, with a volume of 1.13M.
It is down -1.35% in the last 24 hours and down -4.96% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
See More
Previous Close:
$23.71
Open:
$23.68
24h Volume:
1.13M
Relative Volume:
0.61
Market Cap:
$2.30B
Revenue:
$672.72M
Net Income/Loss:
$-575.44M
P/E Ratio:
-4.0078
EPS:
-5.8361
Net Cash Flow:
$-487.00M
1W Performance:
-6.44%
1M Performance:
-4.96%
6M Performance:
-30.37%
1Y Performance:
-34.13%
1-Day Range:
$23.25
$24.12
1-Week Range:
$22.23
$25.17
52-Week Range:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
23.39 | 2.34B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Jefferies Financial Group Inc. Takes $10.97 Million Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Blue Owl Capital Holdings LP Decreases Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Northwestern Mutual Wealth Management Co. Has $4.63 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
J.P. Morgan Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $72 - Moomoo
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $1.41 Million in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook By Investing.com - Investing.com South Africa
RARE Maintained by Cantor Fitzgerald -- Price Target Raised to $96 - GuruFocus
Cantor Fitzgerald Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook - Investing.com
Ultragenyx Pharmaceutical’s SWOT analysis: stock faces pivotal trial results By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical’s SWOT analysis: stock faces pivotal trial results - Investing.com
Ultragenyx Earnings Call Balances Growth and Cash Burn - TipRanks
Ultragenyx Shareholders Approve Incentive Plan, Elect Directors - The Globe and Mail
Ultragenyx director Suliman Shehnaaz sells $144,188 in stock By Investing.com - Investing.com Nigeria
Ultragenyx Pharmaceutical stock (US74930A1043): Shareholders back incentive plan - AD HOC NEWS
Ultragenyx director Suliman Shehnaaz sells $144,188 in stock - Investing.com UK
Ultragenyx (RARE) director receives RSU and stock option grants in new Form 4 - Stock Titan
Ultragenyx (RARE) director sells shares and receives RSU and option awards - Stock Titan
Ultragenyx (RARE) director granted RSUs and stock options as compensation - Stock Titan
Ultragenyx (RARE) director receives RSU and stock option grants - Stock Titan
Ultragenyx (RARE) director Narachi receives RSU and option awards - Stock Titan
[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity - Stock Titan
Ultragenyx (RARE) director Deborah Dunsire granted RSUs and new stock options - Stock Titan
[144] Ultragenyx Pharmaceutical Inc. SEC Filing - Stock Titan
Ultragenyx shareholders approve director elections and incentive plan at annual meeting - Investing.com Nigeria
Ultragenyx (RARE) investors approve incentive plan, board slate and 2026 auditor - Stock Titan
RAREUltragenyx Pharmaceutical Inc. stock news, filings & ratings - Quantisnow
Rare Q1 loss wider than expected, sales down Y/Y on seasonal effect - MSN
Chancery Court Tosses Stockholder Complaint Against Ultragenyx Pharma - Courthouse News
Ultragenyx Pharmaceutical Inc.Common Stock (NQ: RARE - The Chronicle-Journal
Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE) - MarketBeat
UBS Group AG Raises Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - 富途牛牛
HC Wainwright Has Bearish Forecast for RARE Q2 Earnings - MarketBeat
Investigation Alert: Long-Term Investors in Ultragenyx - openPR.com
RARE: Upcoming gene therapy launches and Angelman data drive growth toward 2027 profitability - TradingView
State Street (RARE) reports 5.1% ownership, 5,021,441 shares - Stock Titan
HC Wainwright Brokers Decrease Earnings Estimates for RARE - MarketBeat
State of New Jersey Common Pension Fund D Sells 42,451 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
GTX-102 data show continued developmental gains in Angelman - Angelman Syndrome News
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises - Investing.com India
CCORF Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $79 - Moomoo
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Number of shareholders of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Number of shareholders of Ultragenyx Pharmaceutical, Inc. – FWB:UP0 - TradingView
Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses? - Yahoo Finance
Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):